Asia Pacific T Cell Therapy Market Forecast to 2030 - Regional Analysis - by Modality (Research and Commercialized), Therapy Type [CAR T-cell Therapy and T-cell Receptor (TCR)-based], and Indication (Hematologic Malignancies and Solid Tumors)

List of Tables

The Asia Pacific T cell therapy market was valued at US$ 251.99 million in 2022 and is expected to reach US$ 882.72 million by 2030; it is estimated to grow at a CAGR of 17.0% from 2022 to 2030.

Increasing Number of T-Cell Therapy Approvals Fuels the Asia Pacific T Cell Therapy Market

Targeted treatment, faster and more efficient recovery, and reduced side effects are among the advantages of t cell therapy. Globally, cell therapies are widely adopted owing to the availability of various approvals. For instance, in 2023: Janssen's CAR-T cell therapy CARVYKTI (Ciltacabtagene Autoleucel) has been approved as a fourth-line treatment for multiple myeloma patients by the Therapeutic Goods Administration, Australia.

In 2023: The Chinese National Medical Products Administration has approved the use of Fucaso (equecabtagene autoleucel) by Innovent Biologics and IASO Biotechnology (IASO Bio) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM). In June 2023, the agency approved the therapy's new drug application (NDA).

In 2023: The first humanized CD19-targeted Chimeric Antigen Receptor T cell (CAR-T cell) therapy product, NexCAR19 (Actalycabtagene autoleucel), has been approved by the Central Drugs Standard Control Organization (CDSO) for use in cases of relapsed/refractory B-cell lymphomas and leukemia in India. Immuno Adoptive Cell Therapy is incubated at IIT Bombay.

In 2023: Yikaida (axicabtagene ciloleucel), an autologous CAR T-cell therapy developed by Fosun Kite Biotechnology, was granted approval by China's National Medical Products Administration (NMPA) for use as a second-line treatment for patients with large B-cell lymphoma.

In 2020: The Ministry of Health, Labor and Welfare (MHLW) of Japan has granted the Foundation for Biomedical Research and Innovation at Kobe ("FBRI") a marketing license to produce and distribute Kymriah (tisagenlecleucel) for patients in Japan. Novartis made this announcement today. With this clearance, FBRI is now the only authorized commercial manufacturing facility in Asia for CAR-T cell therapy.

Thus, the increasing number of approvals for T-cell therapy is fueling the market growth.

Asia Pacific T Cell Therapy Market Overview

The Asia Pacific T-cell therapy market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The market in Asia Pacific is expected to witness significant growth as CAR T-cell therapy is efficient in treating cancer, elevating the market growth in the region. Many clinical trials for CAR T-cell therapy are ongoing in the region, offering new opportunities in APAC. China is the largest country in the world for CAR T-cell clinical trials, which hospitals conduct. The CAR-T industry chain is being formed in China, including ongoing and expected regulatory reforms to benefit access to such novel therapies. China approved its first CAR T-cell therapy, relmacabtagene autoleucel of JW Therapeutics, in September 2021 for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) after two or more lines of systemic therapy.

Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)

Asia Pacific T Cell Therapy Market Segmentation

The Asia Pacific T cell therapy market is segmented into modality , therapy type, indication, and country.

Based on modality, the Asia Pacific T cell therapy market is bifurcated into research and commercialized. The commercialized segment held a larger market share in 2022.

Based on therapy type, the Asia Pacific T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held a larger market share in 2022.

Based on indication, the Asia Pacific T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held the largest market share in 2022.

Based on country, the Asia Pacific T cell therapy market is segmented into China, Japan, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific T cell therapy market in 2022.

Bristol-Myers Squibb Co, Gilead Sciences Inc, Innovent Biologics Inc, Janssen Global Services LLC, JW (Cayman) Therapeutics Co Ltd, Legend Biotech Corp, and Novartis AG are some of the leading companies operating in the Asia Pacific T cell therapy market.

Product Code: BMIRE00029304

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Asia Pacific T Cell Therapy Market, by Country (US$ Million)

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Asia Pacific T Cell Therapy Market - Key Industry Dynamics

4.1 Market Drivers:
- 4.1.1 Growing Burden of Cancer Worldwide
- 4.1.2 Increasing Number of T-Cell Therapy Approvals
4.2 Market Restraints
- 4.2.1 Side-effects of CAR T-Cell Therapy
4.3 Market Opportunities
- 4.3.1 Growing Investment in T-Cell Therapy
4.4 Future Trends
- 4.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
4.5 Impact Analysis:

5. T Cell Therapy Market - Asia Pacific Market Analysis

5.1 Asia Pacific T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030

6. Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 - by Modality.

6.1 Overview
6.2 Asia Pacific T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
6.3 Research
- 6.3.1 Overview
- 6.3.2 Research: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Commercialized
- 6.4.1 Overview
- 6.4.2 Commercialized: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

7.1 Overview
7.2 Asia Pacific T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
7.3 CAR T-cell Therapy
- 7.3.1 Overview
- 7.3.2 CAR T-cell Therapy: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 T-cell Receptor (TCR)-based.
- 7.4.1 Overview
- 7.4.2 T-cell Receptor (TCR)-based: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 - by Indication.

8.1 Overview
8.2 Asia Pacific T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
8.3 Hematologic Malignancies
- 8.3.1 Overview
- 8.3.2 Hematologic Malignancies: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- 8.3.3 Asia Pacific T Cell Therapy Market, by Haematological Malignancies, 2020-2030 (US$ Million)
8.4 Solid Tumor
- 8.4.1 Overview
- 8.4.2 Solid Tumor: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific T Cell Therapy Market - Country Analysis

9.1 Overview

10. T Cell Therapy Market-Industry Landscape

10.1 Overview
10.2 Growth Strategies in T Cell Therapy Market
10.3 Organic Growth Strategies
- 10.3.1 Overview
10.4 Inorganic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Legend Biotech Corp
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Janssen Global Services LLC
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Gilead Sciences Inc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Bristol-Myers Squibb Co
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Novartis AG
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 JW (Cayman) Therapeutics Co Ltd
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Innovent Biologics Inc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms